# Mitral Stenosis

Mitral stenosis management hinges on confirming hemodynamic severity, distinguishing rheumatic from calcific anatomy, preventing embolism in atrial fibrillation, and selecting balloon commissurotomy only when rheumatic valve morphology and regurgitation permit durable relief.

**Clinical question:** How should physicians assess and manage rheumatic and calcific mitral stenosis, including anticoagulation and valve intervention?

Updated: 2026-09-15T22:50:40.880962+00:00

## What matters in practice
- Define severe mitral stenosis by mitral valve area of 1.5 cm2 or less; interpret the mean transmitral gradient in the context of flow and heart rate because gradients vary substantially at the same valve area. [21]
- For rheumatic mitral stenosis with atrial fibrillation, use a vitamin K antagonist rather than a direct oral anticoagulant; a target INR of 2.5 is recommended in the cited management review. [1][2][17]
- Percutaneous mitral balloon commissurotomy is the preferred less-invasive intervention for symptomatic severe rheumatic mitral stenosis when valve morphology is favorable and mitral regurgitation is not grade 3 or 4. [16][18]
- Do not apply rheumatic intervention thresholds indiscriminately to mitral annular calcification: calcific mitral stenosis is high risk for intervention and should generally be treated invasively only in highly symptomatic patients. [2]
- Refer patients with severe valve disease being considered for intervention to a multidisciplinary Heart Valve Team or Primary/Comprehensive Valve Center. [2]

## Confirm obstruction and establish rheumatic versus calcific anatomy

Transthoracic echocardiography should establish valve area, gradient, consequences, and intervention-relevant morphology.

Classify severe mitral stenosis when mitral valve area (MVA) is 1.5 cm2 or less. Obtain MVA by direct planimetry when feasible and calculate pressure half-time from the continuous-wave Doppler mitral inflow signal; both are commonly used approaches. [8][9][21]

Do not use mean transmitral gradient as a stand-alone severity measure. At an MVA of 1.5 cm2 or less, mean gradient can vary considerably with hemodynamic profile; document rhythm and heart rate when interpreting a low or high gradient against the anatomic valve area. [21]

The etiologic distinction changes the procedural pathway. Rheumatic disease is the anatomy for which percutaneous mitral balloon commissurotomy (PMBC) is used; favorable features include pliable leaflets and subvalvular apparatus. Calcific mitral stenosis is typically associated with extensive mitral annular calcification, in which planimetry may be inaccurate and abnormal left atrial and left ventricular compliance can produce a high gradient without severe anatomic obstruction. [2][16]
- For rheumatic disease, document leaflet and subchordal pliability and mitral regurgitation grade before selecting PMBC. [16]
- For calcific disease, reconcile MVA with Doppler gradient and chamber compliance rather than treating a gradient alone as proof of severe obstruction. [2]

*Echocardiographic findings that direct the mitral stenosis pathway. [2][8][9][16][21]*

| Finding | Interpretation | Action changed |
| --- | --- | --- |
| MVA ≤1.5 cm2 | Severe mitral stenosis. [21] | Determine symptom burden, rhythm, pulmonary consequences, and candidacy for intervention. [2][16] |
| Discordant MVA and mean gradient | Gradient is flow- and hemodynamic-profile dependent. [21] | Review heart rate, rhythm, valve anatomy, and left-sided compliance before labeling severity. [2][21] |
| Pliable rheumatic leaflets/subvalvular apparatus | Favorable PMBC morphology. [16] | Consider PMBC when severe disease is symptomatic and regurgitation is acceptable. [16][18] |
| Extensive mitral annular calcification | Planimetry may be inaccurate; compliance abnormalities may elevate gradient without severe obstruction. [2] | Avoid extrapolating rheumatic PMBC indications; consider intervention only for highly symptomatic patients at an expert valve center. [2] |

## Select balloon commissurotomy or surgery for rheumatic mitral stenosis

Anatomy and mitral regurgitation determine whether a catheter-based commissural procedure is appropriate.

For symptomatic severe rheumatic mitral stenosis, select PMBC when valve morphology is favorable. The cited criteria emphasize pliability of the leaflets and subchordal apparatus and absence of grade 3 or 4 mitral regurgitation; this approach achieves results similar to surgical valvotomy with less trauma and scarring in the randomized-trial evidence summarized by NICE. [16][18]

When the rheumatic valve is unsuitable for PMBC because morphology is unfavorable or regurgitation is grade 3 or 4, pursue surgical evaluation rather than forcing balloon intervention. Surgical treatment is advised for severe mitral stenosis when morphology is not favorable for PMBC. [16]

Send every patient with severe mitral stenosis being considered for intervention to a multidisciplinary team or Primary/Comprehensive Valve Center. This is particularly important when concomitant valve disease, advanced age, extensive calcification, or major comorbidity makes the procedural risk-benefit assessment nonstandard. [2]
- PMBC is a rheumatic-valve strategy; do not infer suitability from MVA alone. [16]
- Grade 3 or 4 mitral regurgitation is an unfavorable feature for PMBC selection. [16]
- Use surgery when severe rheumatic disease requires intervention but PMBC anatomy is unfavorable. [16]

*Intervention selection in severe mitral stenosis. [2][16][18]*

| Clinical branch | Preferred next step | Key exclusion or tradeoff |
| --- | --- | --- |
| Symptomatic severe rheumatic MS with pliable valve/subvalvular apparatus and no grade 3 or 4 MR | PMBC. [16][18] | Procedure selection depends on morphology, not valve area alone. [16] |
| Severe rheumatic MS with unfavorable PMBC morphology or grade 3 or 4 MR | Surgical evaluation at a valve center. [16] | Balloon commissurotomy is not the preferred route when these features are present. [16] |
| Calcific MS with extensive mitral annular calcification | Reserve intervention for highly symptomatic patients; assess at an experienced valve center. [2] | Extensive calcification, older age, and comorbidity increase intervention risk; rheumatic thresholds do not directly apply. [2] |

## Use vitamin K antagonist anticoagulation for atrial fibrillation with rheumatic mitral stenosis

Rheumatic mitral stenosis is a specific exclusion from the usual native-valve direct oral anticoagulant pathway.

In atrial fibrillation with rheumatic mitral stenosis, prescribe oral anticoagulation with a vitamin K antagonist rather than a non-vitamin K oral anticoagulant. ACC/AHA guidance identifies rheumatic mitral stenosis, along with mechanical prostheses, as the exception to CHA2DS2-VASc-based selection of either agent class for other native valve disease. [2][14][17]

Warfarin is the primary oral anticoagulant option because direct oral anticoagulant trials consistently excluded patients with mitral stenosis. The cited rheumatic mitral stenosis review recommends indefinite therapeutic warfarin with a target INR of 2.5 in the setting of concomitant rheumatic mitral stenosis and embolic risk. [1]

Do not substitute aspirin for therapeutic anticoagulation when rheumatic mitral stenosis coexists with an embolic indication. Historical cohorts before widespread anticoagulation experienced embolic events in more than 25% of patients during the disease course, supporting the high-risk framing in this population. [1]
- Rheumatic MS plus AF: select a vitamin K antagonist. [2][17]
- Native valve disease other than rheumatic MS with AF: a direct oral anticoagulant may be used according to CHA2DS2-VASc assessment. [2][14]
- A cited target for warfarin in rheumatic MS is INR 2.5. [1]

*Anticoagulant selection by valve and rhythm context. [1][2][14][17]*

| Clinical context | Anticoagulant approach | Decision point |
| --- | --- | --- |
| Rheumatic MS with AF | Vitamin K antagonist; cited target INR 2.5. [1][2][17] | Do not use the usual native-valve DOAC pathway. [2][14] |
| Mechanical prosthesis with AF | Vitamin K antagonist. [2][17] | Mechanical prosthesis is also excluded from the DOAC pathway. [2] |
| Native valve disease with AF, excluding rheumatic MS | Vitamin K antagonist or DOAC based on shared decision-making and CHA2DS2-VASc score. [2][14] | This exception framework should not be generalized to rheumatic MS. [2] |

## Approach calcific mitral stenosis and concomitant aortic stenosis cautiously

Calcific obstruction has different diagnostic limitations and substantially different procedural hazards than rheumatic disease.

Calcific mitral stenosis should not be managed as rheumatic commissural fusion. Extensive calcification can prevent accurate planimetered area measurement, while left atrial and left ventricular compliance abnormalities can generate a high gradient without severe fixed obstruction. Invasive treatment is therefore limited to patients who are highly symptomatic, with evaluation at an experienced valve center. [2]

When severe aortic stenosis coexists with mitral stenosis, avoid assuming that mitral intervention should occur first. Treating mitral stenosis first can precipitate severe pulmonary edema by abruptly increasing preload to a small-cavity, low-flow left ventricle downstream from stenotic aortic valve. [5]

If intervention is pursued in extensive mitral annular calcification, recognize the elevated risk created by calcification, advanced age, and comorbidity. Surgical approaches may require complex annular reconstruction or replacement strategies, and transcatheter approaches are considered in patients who are not surgical candidates; neither pathway is a routine analog of rheumatic PMBC. [2][16][5]
- Concomitant severe AS and MS: determine sequencing in a multidisciplinary valve team because mitral-first treatment can cause pulmonary edema. [5]
- Extensive MAC: reserve procedural treatment for highly symptomatic patients after anatomy and hemodynamics are reconciled. [2]

*Management distinctions in rheumatic and calcific mitral stenosis. [2][5][16]*

| Feature | Rheumatic MS | Calcific MS/MAC |
| --- | --- | --- |
| Primary procedural option | PMBC when symptomatic severe disease has favorable morphology and no grade 3 or 4 MR. [16][18] | No analogous routine balloon pathway; intervention only in highly symptomatic patients. [2] |
| Assessment pitfall | Procedure suitability requires leaflet, subvalvular, and MR assessment. [16] | Calcification can impair planimetry; abnormal compliance can elevate gradient without severe obstruction. [2] |
| Risk context | Escalate to surgery if anatomy is unsuitable for PMBC. [16] | Extensive calcification, older age, and comorbidity raise intervention risk. [2] |
| Concomitant severe AS | Not specifically addressed by PMBC criteria. [16] | Mitral-first treatment may trigger pulmonary edema in low-flow severe AS. [5] |

## Use symptoms, hemodynamics, rhythm, and anatomy to trigger reassessment

Repeat evaluation when clinical status changes rather than relying on a prior gradient or valve-area measurement alone.

New or worsening exertional limitation, pulmonary congestion, or atrial fibrillation should prompt repeat transthoracic echocardiography with MVA, mean gradient, rhythm, and assessment of left atrial and pulmonary circulatory consequences. ACC/AHA staging integrates valve anatomy, hemodynamics, left atrial and pulmonary effects, and symptoms rather than a single measurement. [3]

Escalate promptly to a Heart Valve Team when severe disease is symptomatic, when MVA and gradient are discordant, when there is substantial calcification, or when mixed aortic and mitral disease makes sequencing uncertain. A multidisciplinary valve-center review is recommended for severe valve disease under consideration for intervention. [2]

After PMBC or surgical treatment, reassess the residual stenosis and mitral regurgitation using echocardiographic valve-area methods. In patients after mitral valve repair, pressure half-time may not correlate with mean gradient, so interpret the measurement in the postoperative anatomy rather than using preintervention assumptions. [7]
- Repeat echo after a meaningful change in symptoms, rhythm, or congestion to reassess MVA and gradient in current hemodynamic conditions. [3][21]
- Post-repair: recognize that pressure half-time and mean gradient may diverge. [7]
- Severe disease under consideration for intervention warrants valve-center involvement. [2]

*Escalation triggers in mitral stenosis. [2][3][5][7][21]*

| Trigger | Immediate reassessment | Next action |
| --- | --- | --- |
| Symptoms out of proportion to prior study | Repeat echo with MVA, gradient, rhythm, and chamber/pulmonary consequences. [3][21] | Refer for valve-team review if severe disease or discordance persists. [2] |
| High gradient with extensive MAC | Reassess anatomic obstruction and compliance-related gradient elevation. [2] | Restrict intervention consideration to highly symptomatic patients. [2] |
| Severe AS plus MS | Define each lesion's hemodynamic contribution and procedural sequence. [5] | Multidisciplinary review; avoid reflex mitral-first treatment. [5] |
| Post-repair discordant pressure half-time and gradient | Interpret valve area with postoperative anatomy in mind. [7] | Use comprehensive echocardiographic assessment rather than pressure half-time alone. [7] |

## References
1. Management of rheumatic mitral stenosis — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31779-9/fulltext
2. 2020 ACC/AHA Guideline for the Management of Patients ... - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2020.11.018
3. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2014.02.537
4. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease — www.ahajournals.org — https://www.ahajournals.org/doi/pdf/10.1161/circulationaha.108.190748
5. Aortic Valve Disease, Transcatheter Aortic Valve Replacement, and the Heart Failure Patient: A State-of-the-Art Review — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jchf.2023.07.003
6. Epidemiology of Valvular Heart Disease in Asia Pacific Region — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacasi.2025.03.011
7. Assessment of Mitral Valve Area During Percutaneous Mitral Valve ... — www.ahajournals.org — https://www.ahajournals.org/doi/full/10.1161/circimaging.113.000620?doi=10.1161%2FCIRCIMAGING.113.000620
8. Cardiovascular Magnetic Resonance Imaging for Valvular Heart ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circulationaha.107.742486
9. Low‐Gradient Severe Mitral Stenosis: Hemodynamic Profiles ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.118.010736
10. The 2020 ACC/AHA Guidelines for Management of Patients With Valvular Heart Disease: Highlights and Perioperative Implications - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1053077021003396
11. Valve characteristics and surgical options for severe rheumatic mitral stenosis with more than mild regurgitation: A dual-center retrospective study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0022522326000929
12. Outcomes of Severe Mitral Stenosis With the Revised Severity Criteria: Mitral Valve Replacement vs Percutaneous Mitral Valvuloplasty - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0828282X23016598
13. Anesthetic Considerations for Patients with Advanced Valvular Heart Disease Undergoing Noncardiac Surgery - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1932227510000091
14. New in Clinical Documents | Implementing the New ACC/AHA Guideline on Valvular Heart Disease - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2021/01/01/12/42/new-in-clinical-documents-implementing-the-new-acc-aha-guideline-on-valvular-heart-disease
15. Primary mitral regurgitation: answers to clinical cardiologists’ most common questions — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/education/cardiopractice/primary-mitral-regurgitation-answers-to-clinical-cardiologists-most-common-que
16. [PDF] Tendyne Holdings, Inc. CONFIDENTIAL CS0005-P MAC Feasibility ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/58/NCT03539458/Prot_SAP_000.pdf
17. 2020 ACC/AHA guideline for the management of patients with ... — www.jtcvs.org — https://www.jtcvs.org/article/S0022-5223(21)00592-4/fulltext
18. Rationale and impact | Heart valve disease presenting in adults: investigation and management | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng208/chapter/Rationale-and-impact
19. Sex-Related Factors in Valvular Heart Disease - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2021.08.081
20. Mitral Annulus Calcium Score in Patients With Calcific Mitral ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.123.030540
21. Gradient Severe Mitral Stenosis - American Heart Association Journals — www.ahajournals.org — https://www.ahajournals.org/doi/pdf/10.1161/JAHA.118.010736
22. Elevated Mitral Valve Pressure Gradient Is Predictive of Long‐Term ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.118.011366
23. Current Evaluation and Management of Patients With Mitral Stenosis — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.cir.0000029210.14716.01
24. echocardiography and Doppler pressure half-time methods in ... — www.ahajournals.org — https://www.ahajournals.org/doi/pdf/10.1161/01.cir.73.1.100

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.